AtriCure assumed with an Overweight at JPMorgan

JPMorgan analyst Lilia-Celine Lozada assumed coverage of AtriCure (ATRC) with an Overweight rating and $40 price target With numbers reset and competitive headwinds not materializing as feared, the stock is one that investors should pay closer attention to in 2025, the analyst tells investors in a research note. The firm says that despite noise from appendage management competition, AtriCure’s underlying trends in the core business remain solid with healthy market trends and solid growth in areas like Open and Pain Management.